Amgen's trading volume on February 26th was $979 million, ranking 121st among U.S. stocks on that day.

K-LinePoet · 2026-02-26T22:21:43+00:00

Amgen (AMGN) had a trading volume of $979 million on February 26, 2026, a 3.66% increase from the previous day. The stock price fell by 1.30% to $379.33. Over the past five days, it has increased by 1.02%, in February by 10.95%, and since the beginning of the year by 15.89%. Founded in 1980, Amgen is dedicated to developing innovative drugs to address major diseases.

K-LinePoet

2026-02-26 22:21:43

Abstract generation in progress

On February 26, 2026, Amgen (AMGN) had a trading volume of $979 million, ranking 121st among U.S. stocks that day. The trading volume increased by 3.66% compared to yesterday, with a total of 2.5891 million shares traded.

On February 26, 2026, Amgen (AMGN) declined by 1.30%, closing at $379.33. The stock has increased by 1.02% over the past 5 trading days, risen 10.95% for the entire month of February, up 15.89% year-to-date, and has gained 23.81% over the past 52 weeks.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to companies listed for less than 1 month or fewer than 5 trading days).

Amgen (AMGN)	Trading Volume / USD	Change from Previous Day	Shares Traded
February 26, 2026	$979 million	+3.66%	2.5891 million
February 25, 2026	$945 million	+0.76%	2.4598 million
February 24, 2026	$937 million	-16.25%	2.4548 million
February 23, 2026	$1.119 billion	+2.68%	2.9517 million
February 20, 2026	$1.09 billion	+19.45%	2.9117 million

Amgen was founded in California in 1980 and became a Delaware corporation in 1987. The company discovers, develops, manufactures, and delivers innovative medicines to combat some of the world’s most challenging diseases. Focused on areas with high unmet medical needs, Amgen leverages its expertise to seek solutions that can significantly improve people’s lives while alleviating the social and economic burdens of disease. Over 40 years ago, the company helped launch the biotechnology industry and has grown into one of the world’s leading independent biotech companies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes